EU Compassionate Use Programmes (CUPs)
@article{Sou2012EUCU, title={EU Compassionate Use Programmes (CUPs)}, author={H{\'e}l{\`e}ne Sou}, journal={Pharmaceutical Medicine}, year={2012}, volume={24}, pages={223-229} }
For some patients, compassionate use programmes (CUPs) are the only way to access promising medicinal products that are not yet authorized and for which clinical trials are either not available or in which these patients cannot participate. For such patients, the CUP benefits can be very important. Although an EU regulatory framework exists, there is no single, centralized EU-wide procedure for CUPs. Each Member State has its own procedures and CUP approvals are governed by national regulatory… CONTINUE READING
Tables and Topics from this paper
Tables
11 Citations
The Evolving Landscape of Early Access Programmes: Comparisons and Implications for Market Access.
- Computer Science, Medicine
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
- 2015
- PDF
Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs.
- Business, Medicine
- Health policy
- 2018
- 7
Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
- Business, Medicine
- Health policy
- 2019
- 3
Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
- Business, Medicine
- Health policy
- 2019
- 1
- PDF
Roll out of intraveneous artesunate under named patient programmes in the Netherlands, Belgium and France
- Medicine, Biology
- Orphanet Journal of Rare Diseases
- 2013
- 3
Global Access Programs: A Collaborative Approach for Effective Implementation and Management
- Medicine
- Pharmaceutical Medicine
- 2015
- 3
- PDF
Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study.
- Business, Medicine
- Health policy
- 2018
- 2
- PDF
A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
- Medicine
- Chinese journal of cancer
- 2013
- 5
- PDF